Skip to content
orbyd

Filtered library · Theme

immuno-dermatology theme · 1 dossier

Dossiers in the immuno-dermatology theme cluster — 1 name moving on shared catalysts.

All dossiers

NKTR

MEDIUM

REZOLVE-AA Phase 2b primary hit 2026-04-20 (29%/31% SALT response) de-risks REZPEG Treg-IL-2 mechanism; analyst cluster now chasing (BTIG $178, HCW $185, Citi $151, Wedbush $95 Neutral). Same-day $250M secondary caps the squeeze leg — edge…

a5Earnings inflection biotech-precision-therapeutics il-2-treg-conjugate
catalyst · →